Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Abstract

The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.

1 ) A method of fat reduction comprising injecting a sustained release formulation of a compound selected from the group consisting of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs, latanoprost and travoprost and prostaglandin derivatives and mixtures thereof into a fat deposit. 
     
     
         2 ) The method of  claim 1 , wherein the compound is selected from the group consisting of bimatoprost, latanoprost, travoprost and Compound #1 and mixtures thereof. 
     
     
         3 ) The method of  claim 1 , wherein the sustained release formulation is selected from the group consisting of injectable depots, gel suspensions, a ReGel delivery system, a hyaluronic acid release platform, implants, microspheres, macrospheres and injectable solvents. 
     
     
         4 ) The method of  claim 3 , wherein the compound is bimatoprost. 
     
     
         5 ) The method of  claim 1 , wherein the sustained release formulation is injected directly into the fat deposit. 
     
     
         6 ) The method of  claim 1 , wherein the fat reduction is localized fat reduction at and around the injection site. 
     
     
         7 ) The method of  claim 3 , wherein the sustained release formulation is an implant with the formulation of about 20% bimatoprost, about 45% R203s, about 20% RG752s, about 10% R202H and about 5% PEG-3350. 
     
     
         8 ) The method of  claim 1 , wherein the method results in atrophy of both brown and white adipocytes and results in localized fat reduction. 
     
     
         9 ) The method of  claim 7 , wherein the implant releases bimatoprost in the fat deposit for over a period of 100 days. 
     
     
         10 ) The method of  claim 1 , wherein the sustained release formulation releases the compound systemically to target a fat deposit at a location in the body that is not at the location of the sustained release formulation. 
     
     
         11 ) The method of  claim 10 , wherein the sustained release formulations are injected or implanted at a location that permits reduction of abdominal fat deposits, visceral fat deposits, epicardial fat deposits, subcutaneous fat deposits and ectopic fat deposits. 
     
     
         12 ) A composition for use in localized fat reduction wherein the composition is a sustained release composition selected from the group consisting of injectable depots, gel suspensions, a ReGel delivery system, a hyaluronic acid based platform, implants, microspheres, macrospheres and injectable solvents. 
     
     
         13 ) The composition of  claim 12 , wherein the composition further comprises a compound selected from the group consisting of bimatoprost, bimatoprost analogs, bimatoprost prodrugs, prostamides, prostaglandins, prostaglandin analogs, latanoprost and travoprost and prostaglandin derivatives. 
     
     
         14 ) The composition of  claim 12 , wherein the sustained release composition is a Regel delivery system and the compound is bimatoprost. 
     
     
         15 ) The composition of  claim 14 , wherein the composition is injected into a localized fat deposit. 
     
     
         16 ) The composition of  claim 15 , wherein the composition is injected at multiple injection sites into a single localized fat deposit. 
     
     
         17 ) The composition of  claim 15 , wherein the composition releases bimatoprost into the localized fat deposit for over a period of 100 days. 
     
     
         18 ) The composition of  claim 13 , wherein the sustained release formulation is an implant comprised of about 20% bimatoprost, about 45% R203s, about 20% RG752s, about 10% R202H and about 5% PEG-3350. 
     
     
         19 ) The composition of  claim 18 , wherein the composition is injected into at least one selected from the group consisting of abdominal fat deposits, visceral fat deposits, epicardial fat deposits, subcutaneous fat deposits and ectopic fat deposits. 
     
     
         20 ) The composition of  claim 18 , wherein injection of the composition results in atrophy of adipocytes in the localized fat deposit and reduction of localized fat.